Progressive steroid refractory grade IV graft-versus-host disease (GvHD) is generally considered to be a fatal disease. The use of allogeneic bone marrow-derived expanded mesenchymal stromal cells (MSCs) has been reported as a novel treatment for this condition. 1 Recently, Ringden et al. 2 reported potential tissue repair during MSC infusions in patients undergoing allogeneic stem cell transplantation. We found a dissimilar outcome within the gastrointestinal (GI) tract of a child treated with MSCs for steroid refractory GvHD and thus would like to express caution in the interpretation of these findings.
A 15-month-old girl underwent a 6/6-matched unrelated cord blood transplant for a diagnosis of juvenile myelo-monocytic leukemia. Conditioning consisted of intravenous Busulfex 120 mg m À2 daily with targeted drug dosing (day À9 to À6), cyclophosphamide 60 mg kg À1 daily (day À5 and À4) with Mesna prophylaxis, melphalan 140 mg m À2 (day À1) and antithymocyte globulin (ATG-Sangstat Imtix day À6 to À2) at a dose of 2.5 mg kg À1 day À1 . GvHD prophylaxis consisted of cyclosporine 2 mg kg À1 day À1 from day -1 given intravenously with dose adjustment according to the results of regular blood sampling. Prednisolone 1 mg kg À1 day À1 was administered from day þ 5 onward.
She developed systemic adenoviral infection detected by quantitative reverse transcription-PCR and GI infection detected by excretion of adenovirus type 31 in the feces. Although the duration of therapy was prolonged in light of her poor immune reconstitution, she was successfully treated with cidofovir (1 mg kg À1 ; three times per week) and with probenecid for renal protection.
Leukocyte recovery (X0.5 Â 10 9 /l) was observed at day þ 31 post-transplantation and was confirmed by variable number of tandem repeats (VNTR) polymorphic chimerism analysis of circulating peripheral blood mononuclear cells as well as bone marrow, which demonstrated 100% donor signal in both peripheral blood mononuclear cells and granulocytes.
She simultaneously developed profuse diarrhea, hematemesis and severe rectal bleeding requiring massive blood and platelet support. There were no evident skin or liver abnormalities. Endoscopic examination of the recto-sigmoid colon demonstrated severe mucosal sloughing. No biopsy was undertaken because of the risk of perforation. However, the overall appearance was consistent with a diagnosis of severe GvHD. She was started on methyl-prednisolone 2 mg kg À1 day
À1
, resulting in a marked reduction in diarrhea and blood loss, which further supported our clinical diagnosis. The improvement was not maintained and despite further immune suppression, namely, additional steroids and mycophenolate mofetil with tacrolimus replacement for cyclosporine, the severe diarrhea and massive blood losses became almost uncontrollable. Intravenous MSCs from a third party, an unrelated 25-year-old female donor, at a dose of 1.76 Â 10 6 per kg recipient weight, were given 2 months after the onset of GvHD, according to an ethically approved phase II study. These were administered without acute side effects and no evident worsening of her adenoviral infection.
Her GI symptoms resolved completely over a period of 2 weeks, and following a cautious reduction of her immune suppression, she received a further infusion of MSCs from the same donor (1 month after the first infusion) to successfully control a rebound of her diarrhea. Further reduction of immune suppression was uneventful.
Despite this, she developed persistent obstructive upper GI problems with severe gastric retention and bilious aspirates. Upper GI endoscopy was performed, which showed severely inflamed duodenal mucosa and a marked stenosis in the distal duodenum ( Figure 1a ). Dynamic radiological examination showed thinning, marked reduction in the caliber, stenosis and stricturing of the small bowel (Figure 1b) . Peristaltic activity was not evident in the jejunum and ileum. Histopathological examination revealed areas of severe widespread disorganization and atrophy of the villi, fibrosis of the lamina propria and edema (Figure 1c ). These were interspersed by areas of relatively normal mucosa. No lymphocyte infiltration or apoptosis was evident, confirming the resolution of GvHD. The rectum was relatively normal.
At 3 months post-MSC infusion, repeated examination of the GI tract revealed persistent small intestinal pathology with evident fibrosis of the muscularis mucosa and submucosa. Her clinical condition remained stable with no evident underlying hematological disease or GvHD.
One year following MSCs, she remains dependent on total parenteral feeding with no evident functional small bowel tissue or regeneration. In light of these findings, she has been appraised and accepted as a possible candidate for future small bowel transplantation.
Despite advances in pre-transplant immune suppression and donor human leukocyte antigen typing methods (and thus donor selection), acute GvHD remains a significant cause of transplant-related mortality and morbidity following allogeneic hematopoietic stem cell transplantation. 3 The initial management of acute GvHD comprises steroid treatment. Approximately 50% of patients will remit or improve with this treatment, but the remainder will require second-line treatment, whose outcome to date remains unsatisfactory. 4 There is presently no consensus as to salvage treatment in steroid refractory acute GvHD. Acute GvHD is generally considered steroid refractory when there is no response to methyl-prednisolone at 2.0 mg kg À1 day À1 for 1 week, or when there is progressive disease at 72 h with this dose. 3 Recently, the infusion of third party MSCs has been described, which effectively controlled steroid refractory GvHD that had failed all other attempts at treatment. 1 A multicenter analysis has confirmed this initial report, with the majority of children treated, inclusive of this child, showing either complete or partial resolution of symptoms. 5 MSCs are multipotent bone marrow cells and may play a role in modulating a variety of immune responses. 6 The mechanisms underlying the possible in vivo immunomodulatory effects of MSCs remain unknown. MSCs may influence GvHD by secretion of soluble factors by suppressing dendritic cell function or direct cell-to-cell contact with alloreactive T cells. The provision of soluble factors, transdifferentiation or cell fusion have all been suggested the possible means by which MSCs may play a role in tissue healing. 7 In our patient, despite evident control of GvHD, presumably due to the immunomodulatory nature of the infused MSCs, complete repair of the small bowel injury was not achieved by this strategy. However, the timing of MSC infusion related to the onset of refractory GvHD might be an important factor to this irreversible process. Our patient was treated with alternative immune suppression before MSC infusions. It is conceivable that persistent GvHD combined with GI adenoviral infection has contributed to her adverse long-term GI-sequelae. Similarly, we were unable to determine MSC donor cells in biopsy material and can make no comment as to trafficking to the site of tissue damage as was demonstrated in the case presented by Ringden et al. 2 This case, the first to report such extensive tissue damage unrelated to chronic GvHD, highlights the need for further studies of long-term outcome, as new forms of therapy to overcome GvHD become more widespread. MSCs have been shown to provide an excellent alternative strategy for the control of acute steroid refractory GvHD, but our patient demonstrates that additional medical problems may result as survival rates improve following such treatments. More studies are needed to assess the most effective way to administer MSCs, not only for the control of GvHD but also how best to maximize the long-term health of affected individuals.
